<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155154</url>
  </required_header>
  <id_info>
    <org_study_id>09-130</org_study_id>
    <nct_id>NCT01155154</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis for Simple Hand Lacerations</brief_title>
  <official_title>Antibiotic Prophylaxis for Prevention of Infection in Emergency Department Patients With Simple Hand Lacerations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Staten Island University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kings County Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Downstate Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Question: In emergency department patients with simple hand cuts, do prophylactic
      antibiotics reduce the risk of wound infections?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Simple hand lacerations, defined as hand lacerations that do not involve special structures
      such as bones, tendons, vessels, or nerves, are common in the emergency departments. The
      exact rate of infection in such wounds is unclear. It is also not clear whether prescribing
      prophylactic antibiotics reduces the risk of infection in simple hand lacerations. The
      objective of this randomized double blind controlled study is to: 1. Identify the rate of
      infection in simple hand lacerations, 2. Identify factors or wound characteristics that
      increase the risk of infection, and 3. Assess whether prescribing prophylactic antibiotics
      decreases the risk of infections in such wounds compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Presence of Wound Infection</measure>
    <time_frame>2 weeks</time_frame>
    <description>Hand lacerations will be examined 10-14 days after initial wound closure and will be assessed for presence of infection.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Simple Hand Lacerations</condition>
  <arm_group>
    <arm_group_label>clindamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cepahlexin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cephalexin</intervention_name>
    <description>500 mg (two 250 mg capsules) every 6 hours for 7 days</description>
    <arm_group_label>cepahlexin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin</intervention_name>
    <description>300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days</description>
    <arm_group_label>clindamycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Two placebo capsules every 6 hours for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients (â‰¥ 18 years of age) presenting to the ED with simple hand
             lacerations. Anatomically, lacerations distal to the radial carpal ligament will be
             considered &quot;hand&quot; lacerations. &quot;Simple&quot; or &quot;uncomplicated&quot; laceration refers to one
             that does not involve any special tissue (bone, tendon, blood vessel, or nerve).

        Exclusion Criteria:

          -  Immunocompromised patients (cancer, chemotherapy, transplant, HIV/AIDs)

          -  Current or recent (within two weeks) use of any antibiotics

          -  Allergy to clindamycin or cephalexin

          -  Bites (e.g. dog, cat, or human)

          -  Lacerations resulted from crush injury

          -  Lacerations involving bone, tendon, blood vessel, or nerve

          -  Lacerations inflicted more than 12 hours prior to ED visit

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shahriar zehtabchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Downstate Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York, Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>January 3, 2014</results_first_submitted>
  <results_first_submitted_qc>October 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Downstate Medical Center</investigator_affiliation>
    <investigator_full_name>Shahriar Zehtabchi</investigator_full_name>
    <investigator_title>Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>wounds and lacerations</keyword>
  <keyword>hand</keyword>
  <keyword>infection</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>antibacterial agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clindamycin</title>
          <description>clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
clindamycin: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Cepahlexin</title>
          <description>cephalexin: 500 mg (two 250 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>placebo: Two placebo capsules every 6 hours for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The median age of the subjects was 40 years (quartiles: 29, 53), and 71% were male (n=52).</population>
      <group_list>
        <group group_id="B1">
          <title>Clindamycin</title>
          <description>clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
clindamycin: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Cepahlexin</title>
          <description>cephalexin: 500 mg (two 250 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>placebo: Two placebo capsules every 6 hours for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="B2" value="42" lower_limit="32" upper_limit="58"/>
                    <measurement group_id="B3" value="40" lower_limit="29" upper_limit="52"/>
                    <measurement group_id="B4" value="41" lower_limit="29" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Presence of Wound Infection</title>
        <description>Hand lacerations will be examined 10-14 days after initial wound closure and will be assessed for presence of infection.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clindamycin</title>
            <description>clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
clindamycin: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Cepahlexin</title>
            <description>cephalexin: 500 mg (two 250 mg capsules) every 6 hours for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo: Two placebo capsules every 6 hours for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Presence of Wound Infection</title>
          <description>Hand lacerations will be examined 10-14 days after initial wound closure and will be assessed for presence of infection.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clindamycin</title>
          <description>clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
clindamycin: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Cepahlexin</title>
          <description>cephalexin: 500 mg (two 250 mg capsules) every 6 hours for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>placebo: Two placebo capsules every 6 hours for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Metal After-taste in th mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shahriar Zehtabchi</name_or_title>
      <organization>SUNY Downstate Medical Center</organization>
      <phone>718-245-2973</phone>
      <email>shahriar.zehtabchi@downstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

